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ABSTRACT
Trimetazidine (TMZ) is a metabolic reprogramming agent able to partially 
inhibit mitochondrial free fatty acid β-oxidation while enhancing glucose oxidation. 
Here we have found that the metabolic shift driven by TMZ enhances the myogenic 
potential of skeletal muscle progenitor cells leading to MyoD, Myogenin, Desmin 
and the slow isoforms of troponin C and I over-expression. Moreover, similarly to 
exercise, TMZ stimulates the phosphorylation of the AMP-activated protein kinase 
(AMPK) and up-regulates the peroxisome proliferator-activated receptor gamma 
coactivator 1-α (PGC1α), both of which are known to enhance the mitochondrial 
biogenesis necessary for myoblast differentiation. TMZ also induces autophagy which 
is required during myoblast differentiation and promotes myoblast alignment which 
allows cell fusion and myofiber formation. Finally, we found that intraperitoneally 
administered TMZ (5mg/kg) is able to stimulate myogenesis in vivo both in a mice 
model of cancer cachexia (C26 mice) and upon cardiotoxin damage. Collectively, 
our work demonstrates that TMZ enhances myoblast differentiation and promotes 
myogenesis, which might contribute recovering stem cell blunted regenerative 
capacity and counteracting muscle wasting, thanks to the formation of new myofibers; 
TMZ is already in use in humans as an anti-anginal drug and its repositioning might 
impact significantly on aging and regeneration-impaired disorders, including cancer 
cachexia, as well as have implications in regenerative medicine.
INTRODUCTION
The adult myogenic response plays a key a role in 
the maintenance of skeletal muscle homeostasis. Typically, 
adult myogenesis is triggered by skeletal muscle injuries 
which lead to induction of new myofiber regeneration 
mainly sustained by resident myogenic satellite cells 
(SCs), located underneath the basal lamina of myofibers 
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[1–3]. Upon injury, SCs become activated and differentiate 
into proliferating myoblasts expressing typical myogenic 
markers such as Desmin, Myf-5 and MyoD [4, 5]. Further 
differentiated myoblasts, characterized by the expression 
of other markers such as neonatal isoform of myosin 
heavy chain (neoMyHC), myogenin and slow-twitch 
skeletal muscle troponin T and C, stop proliferating and 
eventually fuse to pre-existing myotubes or to each other 
to form new myotubes [6, 7].
Alterations of the myogenic response have been 
associated with several chronic muscle diseases; in 
muscular distrophies, for example, continuous cycles of 
degeneration-regeneration lead to the consumption of the 
reservoir of SCs and the muscle tissue is progressively 
replaced by connective tissue [8, 9]. The impairment 
of adult myogenesis efficacy also contributes to the 
pathogenesis of sarcopenia in the elderly and, most likely, 
also to muscle wasting occurring in cancer cachexia [10–
17]. Recent data show that the defects in regeneration are 
not only due to a reduced amount of SCs but also to their 
impaired functionality and myogenic capacity, which have 
been associated, among the other causes, with alterations 
in apoptosis, autophagy and reduced activation of 
specific signaling pathways [18–23, 24–27]. In particular, 
defective autophagy in SCs results in the accumulation 
of toxic intracellular debris mainly composed of altered 
mitochondria which leads to senescence [25, 26]. It has 
been proposed that, in order to maintain their energy 
levels and survive in nutrient poor conditions, SCs rely on 
autophagy and that during the transition from quiescence 
to activation, sirtuin 1 (SIRT1) is required for autophagy 
induction in order to meet bioenergetic demands [28].
Energy management and metabolic reprogramming 
seem to be crucial for stem cell differentiation. In this regard, 
favoring the oxidative metabolism has been proposed to 
enhance myogenic capabilities [29–32]. Studies supporting 
the key role of metabolism in controlling stem cell fate 
[33–36] also highlight that mitochondrial metabolism 
pathways lead to reactive oxygen species (ROS) generation 
and modulate acetyl-CoA and NAD/NADH or AMP/ATP 
ratios, all of which are known to regulate SC self-renewal 
and homeostasis [37, 38]. In line with these observations, 
it has recently been found that, during the transition from 
quiescence to proliferation, SCs experience a metabolic 
switch which decreases NAD+ levels and SIRT1 deacetylase 
activity, thus increasing epigenetic histone acetylation and 
activation of muscle gene transcription [39]. Notably, it has 
been shown that slow muscles, characterized by an oxidative 
metabolism, contain a relatively higher number (up to 6 fold) 
of SCs compared to fast-glycolytic muscles [40, 41].
Based on these premises underlining the relevance 
of metabolism reprogramming in controlling stem cell 
fate, we decided to analyze the influence of the metabolic 
modulator Trimetazidine (TMZ) –a partial inhibitor or free 
fatty acid β-oxidation able to enhance glucose oxidation– 
on myoblast survival and differentiative potential. A 
group of drugs referred to as metabolic modulators has 
been extensively studied for their beneficial effects on 
myocardium due to their ability to optimize metabolism 
[42–46]. In particular, among them, TMZ shifts the 
energy metabolism from fatty acid oxidation to glucose 
oxidation by inhibiting the mitochondrial long-chain 
3-ketoacyl coenzyme A thiolase. This change optimizes 
cell metabolism since glucose is a more efficient substrate 
for ATP synthesis than fatty acids; in fact, fatty acids have 
a lower P/O ratio compared to carbohydrates since their 
β-oxidation generates a larger amount of ATP compared to 
glucose oxidation but at the expense of a greater oxygen 
consumption [42]. This accounts for a cytoprotective role 
of TMZ which, as established by a large number of clinical 
studies, exerts a clear beneficial effect in patients with 
ischaemic cardiomyopathy; increased exercise tolerance 
and a decreased angina have been reported compared to 
placebo. Therefore, TMZ has been approved for its use 
in humans for the treatment of chronic stable angina as 
monotherapy and adjunct therapy [42–46]. Notably, TMZ 
has recently been found to also act on skeletal muscle 
being able to protect skeletal myotubes in vitro from 
atrophy due to TNFɑ and to serum starvation by triggering 
the Akt pathway. Moreover, TMZ has also been shown to 
increase strength in mouse models of aging [47, 48] and in 
C26 cachectic mice [49].
RESULTS
TMZ enhances differentiation of C2C12 
myoblasts
In order to explore the effect of metabolic 
modulation on skeletal myoblast differentiation, we 
induced C2C12 myoblasts to differentiate by culturing 
them on DM in presence or absence of various 
concentrations of TMZ (1-5-30 μM). We evaluated the 
extent of differentation after 48h of DM incubation by 
immunostaining for MyHC used as marker for terminal 
myogenic differentiation. As can be observed in Figure 
1A, the administration of TMZ caused an increase of 
MyHC-positivity compared to untreated cells. Since the 
effect of TMZ on C2C12 cells was more reproducible by 
using 5 μM TMZ we continued using this concentration 
throughout the present study, unless otherwise stated.
The effect of TMZ on C2C12 differentiation was 
also evaluated by calculating the fusion index which 
indicates the formation of multinucleated myotubes. 
We found that TMZ determines an increase of the 
fusion index by around 75% compared to untreated 
cells (Figure 1A, right panel graph). The fusion index 
was obtained by calculating the average of nuclei in 
MyHC-positive myotubes (containing more than 3 
nuclei) normalized to the total number of nuclei [50]. 
The increased fusion triggered by TMZ is also evident 
at 72h of DM incubation (Figure 1B) and longer 
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incubation times display very large myotubes in which 
the increased fusion effect and the hypertrophic effect of 
TMZ, previously revealed by treating mature myotubes 
[47], might have been additive (Supplementary 
Figure 1).
Overexpression of myogenic genes is triggered 
by TMZ
To confirm our data suggesting a potentiation 
of the myogenic program by TMZ, we analyzed the 
Figure 1: TMZ enhances C2C12 skeletal myoblast differentiation. (A) Representative pictures of C2C12 myoblasts differentiating 
for 48 hours in differentiating medium (DM) in the absence (Ctrl) or presence (TMZ) of different concentrations of TMZ and then stained 
with anti-MyHC antibody (green) and DAPI (blue) for nuclei detection. Quantification of fusion index after these treatments is shown in 
the histogram on the right. At least 30 fields were analyzed for each condition in four independentexperiments. Data are mean ± s.e.m. ***p 
≤ 0.005 by two-tailed Student’s t-test. Scale bar: 150 μm. (B) Representative pictures of C2C12 myoblasts differentiating for 72 hours in 
DM in the absence (Ctrl) or presence (TMZ) of TMZ. The higher level of fusion with TMZ is highlighted by the enlargement of the red 
labeled area. Scale bar: 100 μm.
Oncotarget113941www.impactjournals.com/oncotarget
expression levels of some muscle-specific genes during 
differentiation with or without supplementation of TMZ 
(Figure 2A). In accordance with our observations reported 
in Figure 1, we found that TMZ triggers a marked increase 
of MyoD, Myogenin and Desmin transcript levels at 24h, 
48h and 72h from the onset of differentitation. MyHC 
also increases after 24h and 48h of DM-TMZ incubation. 
The effect of TMZ was also evaluated at protein level by 
performing the immunofluorescent detection of MyoD 
and Myogenin after 8h and 48h, respectively, from 
DM incubation. As shown in Figure 2, the number of 
nuclei positive for MyoD or Myogenin increases upon 
TMZ administration (Figure 2B, 2C). These results 
clearly indicate a TMZ-dependent enhancement of the 
differentiation programm in C2C12 cells.
Exposure to TMZ promotes a parallel 
orientation of myotubes
The correct orientation of myocytes is crucial for 
myotube formation and a correct myofiber orientation 
allows a longitudinal contraction of the muscle. Cell 
alignment, which is the parallel apposition of the long axes 
of myoblasts/myocytes, precedes fusion. We observed 
that TMZ affects myocyte orientation by enhancing 
the parallelism among cells, this possibly improving 
fusion and promoting myotube formation (Figure 3A). 
Moreover, similarly to a previous report showing that 
the application of a static magnetic field to C2C12 cells 
enhances the parallelism among cells and also induces 
myotube hypertrophy [51], we observed an increase of 
the diameter of myotubes treated with TMZ (Figure 1B 
and 3A). We therefore propose that exposure to TMZ also 
stimulates myotube differentiation by affecting myocyte 
orientation. MyoD and MyHC protein levels also increase 
in the presence of TMZ (Figure 3B). TMZ being a 
metabolic modulator, we evaluated the activation of the 
energetic sensor AMPK which, interestingly, resulted 
over-phosphorylated (Figure 3B). In line with our recent 
observations in mice [49], we also found an up-regulation 
of the peroxisome proliferator-activated receptor gamma 
coactivator 1-alpha (PGC1ɑ) transcript levels in the 
presence of TMZ and an increase of the mitochondrial 
transporter of fatty acids, carnitine palmitoyl transferase 1 
(CPT1) transcript (Figure 3C), possibly as a compensative 
response to the reduction of free fatty acid β-oxidation. 
Accordingly, also PGC1ɑ protein was over-expressed by 
TMZ treatment (Figure 3B).
TMZ does not affect C2C12 proliferation rate, 
apoptosis and ROS levels
In order to evaluate the extent of cell proliferation 
whose alteration might also affect the number of 
differentiating cells, we evaluated 5-bromo-2’-
deoxyuridine (BrdU) incorporation on C2C12 myoblasts 
treated or not with TMZ for 24h, both in GM and in 
DM. In neither case did we observe a different rate of 
proliferation (as shown by the % of BrdU-positive cells) in 
TMZ-treated cells compared to their control counterparts 
(Figure 4A).
To confirm these data we also performed cell cycle 
analysis by propidium iodide (PI) staining and FACS 
analysis in GM- and DM-incubated C2C12 cells in 
presence or absence of TMZ for 24h. No differences were 
observed in the percentage of resting cells (G0/G1) nor in 
that of proliferating cells (S/G2), this confirming that TMZ 
does not affect the rate of cell proliferation (Figure 4B). 
Of note, we obtained the same results by treating the cells 
with TMZ for 48h (Supplementary Figure 3).
These experiments also revealed that the sub-G1 
cell population, which correlates with the percentage of 
dead cells, does not significantly vary with TMZ (Figure 
4B). This is also evident in Figure 1, 3, 4 and 5A, where 
the analysis of the morphology of DAPI-stained nuclei 
shows the absence of picnosis and fragmented nuclei 
as signs of apoptosis, due to TMZ. In order to further 
assess the extent of apoptosis, we also evaluated active 
Caspase-3 and PARP cleavage by WB analysis and, as 
expected, we found no difference between TMZ-treated 
(both at 5 μM but also at the higher concentration 30 
μM) and untreated C2C12 myoblasts (Figure 4C). The 
cleaved form of Caspase-3 is not detectable anywhere. 
Finally, we measured ROS production, which might 
affect cell viability, by DCF staining and flow cytometry 
in C2C12 myoblasts. This analysis showed that TMZ 
incubation for 1h and for 24h does not alter ROS levels 
(Supplementary Figure 3). We can therefore conclude 
that TMZ neither alters cell proliferation rate nor does 
it induce apoptosis or ROS production in C2C12 cells 
during differentiation.
Atrophy genes and autophagy are influenced by 
TMZ in differentiating C2C12
Based on the recently suggested relevance of 
autophagy to myoblast differentiation [52], and given that 
TMZ is able to induce autophagy in mature myotubes 
[47], we also analyzed autophagy during myoblast 
differentiation by determining LC3-II protein levels and 
the LC3-II/LC3-I ratio which we found to be increased in 
the presence of TMZ during C2C12 differentiation (Figure 
4D). Additionally, a deeper analysis of the effects of TMZ 
during C2C12 differentition shows that the transcript 
levels of factors involved in myotube hypotrophy, 
namely atrogin-1/MAFbx and myostatin, decrease in 
TMZ-treated C2C12 myoblasts cultured in DM for 24h, 
to progressively return to control levels at 48h and 72h 
(Figure 4E), while MuRF-1 mRNA levels are not affected 
by TMZ in the same conditions (Figure 4E). We speculate 
that, since TMZ inhibits NF-kB [53, 54] which is related 
to Atrogin expression, this might cause a reduction of 
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Atrogin [55]. However, this point needs to be elucidated 
by additional studies. These data confirm that our findings 
showing atrophy genes down-regulation and autophagy 
stimulation evoked by TMZ in C2C12 myotubes [47] also 
occur during myogenic differentiation.
TMZ accelerates myogenic maturation of SCs
In order to investigate whether the ability of the 
metabolic modulator TMZ to accelerate myogenic 
differentiation is extended also to primary cells, we 
Figure 2: Myogenic genes are overexpressed upon TMZ treatment. (A) The mRNA levels of MyoD, Myogenin, Desmin and 
MyHC, were evaluated by quantitative real time PCR in C2C12 differentiating (for 24, 48 and 72 hours in DM) myoblasts treated (TMZ) or 
not (Ctrl) with 1 μM or 5 μM TMZ. Data were normalized to 18S used as internal control. Data display the percentage of mRNAs relative 
to untreated cells (24h in DM), which was arbitrarily set as 1. Data shown are the mean ± s.e.m. from three experiments each performed in 
triplicate. *p ≤ 0.05, **p ≤ 0.01 and ***p≤ 0.005 by two-tailed Student’s t-test. (B) Representative pictures of C2C12 myoblasts differentiating 
for 8 hours in DM in the absence (Ctrl) or presence of 5μM TMZ (TMZ) and then stained to detect MyoD (green) and nuclei (DAPI, blue). 
Five experiments were performed. Scale bar: 75 μm. (C) Representative pictures of C2C12 myoblasts differentiating for 48 hours in DM 
in the absence (Ctrl) or presence of 5μM TMZ and then stained to detect Myogenin (red), MyHC (green) and nuclei (DAPI, blue). Five 
experiments were performed. Scale bar: 75 μm.
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Figure 3: TMZ enhances the alignment of differentiating myoblasts. (A) Representative pictures of C2C12 myoblasts 
differentiating for 48 hours and 72 hours in DM in the absence (Ctrl) or presence of 5 μM TMZ (TMZ) and then stained to detect MyHC 
(green) and nuclei (DAPI, blue). Scale bar: 150 μm. n = number of analyzed cells; r = mean vector length (statistic of Rayleigh test); p = 
observed significance. The mean vector length r can range from 0 (perfect isotropy; of multiple cell directions) to 1 (perfect anisotropy; 
existence of a preferred-aligned-cell direction). Three independent experiments for each condition were performed, with a total of not less 
than 300 cells analyzed for each condition. (B) Extracts from untreated control C2C12 (Ctrl) and 10μM TMZ-treated C2C12 cells (TMZ) 
were assayed for MyoD, pAMPK, AMPK, PGC-1α and MyHC protein levels. Protein levels of a representative experiment out of three 
are shown. α-tubulin was used as loading control. Density of immunoreactive bands was calculated using the ImageQuant TL software 
from GE Healthcare Life and normalized for α-tubulin. Each value indicates the mean± s.e.m. (reported as percentage of Ctrl) of the 
densitometric analysis on three independent immunoblots. *p ≤ 0.05, **p ≤ 0.01 and ***p≤ 0.005 by student t-test. (C) The mRNA levels 
of PGC-1α and CPT1, were evaluated by quantitative real time PCR in C2C12 differentiating (for 24, 48 and 72 hours in DM) myoblasts 
treated (TMZ) or not (Ctrl) with 1 μM or 5 μM TMZ. Data were normalized to 18S used as internal control. Data display the percentage of 
mRNAs relative to untreated cells (24h in DM), which was arbitrarily set as 1. Data shown are the mean ± s.e.m. from three experiments 
each performed in triplicate. *p ≤ 0.05, **p ≤ 0.01 and ***p≤ 0.005 by two-tailed Student’s t-test.
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Figure 4: TMZ influence on proliferation, apoptosis, autophagy and atrophy markers. (A) Representative images of BrdU 
incorporating C2C12 cells (green) treated for 24 hours with or without 5 μM TMZ in GM and in DM. During the last 4h of incubation, 
cells were labeled with BrdU. Nuclei were stained with DAPI (blue). Four experiments were performed. Scale bar: 75 μm. (B) Cell cycle 
analysis of C2C12 in GM or DM for 24 hours with or without 5 μM TMZ. Cells were then stained with propidium iodide. Histograms show 
the mean ± SE of four independent experiments. No difference were observed in resting (G0/G1) and proliferating cells (S/G2) nor in the 
percentage of hypodiploid apoptotic (sub-G1) cells. (C) Total extracts of differentiating myoblasts kept for 24 hours in DM untreated (Ctrl) 
or TMZ-treated (5 μM and 30 μM) were assayed for PARP and Caspase-3 cleavage and (D), also kept for 48 hours in DM, for LC3 and 
p62. The cleaved form of Caspase-3 is undetectable in each condition. Protein levels of a representative experiment out of three are shown. 
ɑ-tubulin was assayed as a control for equal protein loading. (E) The mRNA levels of Atrogin-1, Murf1 and Myostatin were evaluated by 
quantitative real time PCR in differentiating (for 24, 48 and 72 hours in DM) C2C12 treated or not (Ctrl) with 1 μM or 5 μM TMZ. Data 
were normalized to 18S. Data display the percentage of mRNAs relative to untreated cells for 24 hours in DM, which was arbitrarily set as 
1. Data shown are the mean ± s.e.m. from three experiments each performed in triplicate. ***p≤ 0.005 by two-tailed Student’s t-test.
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Figure 5: Myogenic gene expression and fusion increase in TMZ-treated SCs. (A) Representative images of satellite cells in 
culture for 72 hours, the last 48 hours of which treated (TMZ) or not (Ctrl) with 50 μM TMZ for the last 48 hours. Our previous esperiments 
showed that a higher concentration of TMZ is needed for the treatment of SCs compared to C2C12 cells. Cells were incubated with an 
anti-myogenin antibody (green) and with DAPI (blue). Scale bar: 75 μm. (B) Representative images of satellite cells in culture for 96h the 
last 48h of which treated (TMZ) or not (Ctrl) with 50 μM TMZ for the last 48 hours. Cells were incubated with an anti-myogenin antibody 
(green) and with DAPI (blue). Quantification of fusion index is shown in the histograms on the right. At least 20 fields were analyzed 
for each condition in four independentexperiments. Scale bar: 75 μm. Data are means ± SEM. **P < 0.01 and ***P < 0.005. For myotube 
orientation measurement, three independent experiments for each condition were performed, with a total of not less than 300 cells analyzed 
for each condition. n = number of analyzed cells; r = mean vector length (statistic of Rayleigh test); p = observed significance. The mean 
vector length r can range from 0 (perfect isotropy; of multiple cell directions) to 1 (perfect anisotropy; existence of a preferred-aligned-cell 
direction).
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treated freshly isolated murine SCs with TMZ. Purity of 
SCs ranged from 88% to 99% (Supplementary Figure 
2). As can be observed by immunofluorence staining, at 
early time points of differentiation (Figure 5A; 72h), the 
number of SCs expressing myogenin increases upon TMZ 
treatment, compared to untreated cells. In accordance with 
our observations obtained in C2C12 cells, at later time of 
differentiation (96h), the level of fusion in TM-treated 
cells is markedly higher (73%) than in control cultures 
(Figure 5B). Notably, we also observed that TMZ-treated 
SCs were more aligned. Finally, Desmin, Myogenin and 
MyHC transcript levels significantly increased after TMZ 
treatment while the increase was moderate for Pax7 and 
MyoD (Figure 6). Interestingly, also PGC1ɑ and the slow 
isoforms of Troponin C and I (TNN C and TNN I), which 
are known to be over-expressed during differentiation, are 
up-regulated by TMZ; this further indicates a boosting of 
the differentiative potential triggered by TMZ.
TMZ stimulates in vivo myogenesis both upon 
cardiotoxin (CTX) damage and in cachectic mice
Given the effect of TMZ on myoblast differentiation 
in vitro, we evaluated if TMZ was able to improve 
regeneration upon damage; for this purpose, muscle injury 
was induced in C57BL6 mice by CTX injection [56] and 
the animals were exposed to TMZ. At day 5 post-CTX 
injection, we found that Myo D, Myogenin and Desmin 
mRNA levels were significantly higher in TMZ treated 
CTX mice (CTX TMZ) compared to untreated CTX mice 
(CTX), suggesting that TMZ promotes myogenesis (Figure 
7A). The levels of Pax7 do not change significantly and, 
notably, the levels of the pro-inflammatory cytokine 
MCP1 (Monocyte Chemoattractant Protein-1) tend to 
decrease following TMZ treatment, this excluding that 
the higher myogenesis we found upon TMZ-treatment is 
caused by a deleterious effect of this drug (Supplementary 
Figure 4).
We then evaluated the cross-sectional area (CSA) 
of regenerating myofibers identified by the presence of 
central nuclei. We found that, at day 5 after CTX injection, 
the frequency histograms of the centronucleated fiber 
area delineate a different size distribution in muscles 
of TMZ-treated vs untreated mice; in detail, in TMZ-
treated animals there is a higher number of very small 
centronucleated myofibers (Figure 7B; see fibers smaller 
than 400 μm, on the left side of the histogram), but also 
a higher number of very large centronucleated myofibers 
compared to untreated mice (Figure 7B; see fibers bigger 
than 1000 μm, on the right side of the histogram). To 
explain this behaviour, we hypothesize a double action 
of TMZ which, on one side, might be able to accelerate 
the growth in size of regenerating myofibers (e.g. by 
promoting a higher fusion rate and this might be why we 
observe more big fibers compared to untreated mice), and, 
on the other side, might keep promoting new myofibers 
formation (very small fibers occurring). This second 
potentiating effect on new myogenesis correlates with the 
enhanced expression of myogenic transcripts (Figure 7A). 
This bimodal distribution of myofibers also occurs later 
on, at day 15 post-CTX injection (Figure 7C), although, 
at this later stage, the percentage of centronucleated 
myofibers significantly decreases with TMZ compared 
to Ctrl (Figure 7C) and the frequency histogram on the 
total number of myofibers shows a shift toward the right 
side of the graph with TMZ (Supplementary Figure 5A), 
which mainly supports the acceleration effect of TMZ 
on muscle regeneration. Moreover, the levels of MyoD, 
myogenin and eMHC mRNAs are also higher in TMZ-
treated than in control mice at day 10 post-injury (data 
not shown) when, accordingly, the frequency histogram, 
both on centronucleated and on the total number of 
myofibers, shows a shift toward the left side of the 
graph (Supplementary Figure 5B and data not shown), 
supporting the hypothesis that TMZ also triggers a 
stronger myogenesis, mainly at earlier time points. A 
relevant hypertrophic effect of TMZ on myofibers of not 
damaged muscles has been excluded by our previous work 
[49] and has now been confirmed by CSA analysis of 
controlateral muscles at day 15 post-CTX injection (data 
not shown).
An impaired regenerative response has been evoked 
as contributing to muscle mass loss in cachexia [14, 15, 
17]. In order to clarify the effect of TMZ in pathologies 
characterized by an altered regenerative machinery, we 
evaluated the activation of myogenesis in an in vivo model 
of cancer cachexia (C26-bearing mice). Interestingly, 
we observed an up-regulation of MyoD and Myogenin 
in TMZ-treated C26 hosts (Figure 7D), suggesting that 
TMZ is able to release, partially, at least, the impaired 
myogenesis occurring in C26-bearing mice also without 
decreasing Pax7 [14, 15], and to promote new myofiber 
formation, this being potentially protective against muscle 
wasting. Indeed, Pax7 is not only required to promote the 
proliferation of undifferentiated cells, but is also necessary 
for the myogenic differentiation to proceed [14, 57].
Our experiments indicate that TMZ enhances the 
skeletal muscle regenerative process, both by accelerating 
it and by keeping stimulating new myofiber formation, 
while decreasing inflammation.
DISCUSSION
The present study shows that TMZ exerts a profound 
effect on myogenic precursor cells by altering their gene 
expression profile and supporting and accelerating their 
differentiation in vitro, while enhancing myogenesis 
in vivo. These effects likely depend on the metabolic 
shift and metabolism optimization induced by the drug 
[42]. This is consistent with the knowledge that the 
differentiation of myoblasts is associated with a metabolic 
shift from a predominantly glycolytic state to a metabolism 
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based mainly on mitochondrial oxidative phosphorylation; 
this shift is thought to be needed to support the higher 
energetic demand of contractile muscle [52].
Modulation of metabolic pathways is known to 
regulate SC homeostasis and fate; SC niche environment 
modification influences SC metabolism, this inducing, 
along with the triggering of other signaling pathways, SC 
activation. We found that the metabolic changes induced 
by TMZ have a similar effect on SCs by potentiating their 
myogenic program. Similarly, the reprogramming of SC 
metabolism due to nutrient-dependent changes driven by 
caloric restriction (CR) or by exercise, has been found to 
increase SC myogenic activity, both in young and old mice, 
in concert with an increase in mitochondrial biogenesis 
and metabolic regulators [31, 32, 58]. In fact, the effects of 
both CR and exercise appear to be mediated by the energy 
sensor AMPK that acts on mitochondrial regulators such 
as SIRT1 and PGC1ɑ [32, 37]. PGC1ɑ is a key regulator 
of the exercise-mediated muscle adaptation and our 
experiments showing that TMZ is able to promote PGC1ɑ 
Figure 6: Myogenic genes are overexpressed upon TMZ treatment in SCs. The mRNA levels of MyoD, Pax7, MyoD, Desmin, 
Myogenin, MyHC, PGC1ɑ, slow Troponin C (TNN C) and slow Troponin I (TNN I) were evaluated by quantitative real time PCR in 
primary SCs differentiating for 48 hours and 72 hours and, in the case of SCs differentiating for 72 hours, treated for the last 24 hours with 
10 μM or 50 μM TMZ. Data were normalised to 18S used as internal control. Data display the percentage of mRNAs relative to control 24 
hours DM, which was arbitrarily set as 1. Data shown are the mean ± s.e.m. from four experiments each performed in triplicate. *p < 0.05, 
**p ≤ 0.01 and ***p≤ 0.005 by two-tailed Student’s t-test.
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activation, as well as AMPK over-phosphorylation, (which 
is known to positively regulate PGC1ɑ) also support our 
recent observation that TMZ produces, in vivo, effects 
similar to those induced by exercise [49]. Moreover, 
Figure 7: TMZ stimulates new myofiber formation in vivo. (A) The mRNA levels of Pax7, MyoD, Myogenin (Myog), Desmin 
and MCP1 were evaluated by quantitative real time PCR and were normalised to 18S used as internal control in TA muscles of untreated 
mice (Ctrl), cardiotoxin (CTX)-injured mice (CTX), TMZ-treated mice (Ctrl TMZ), and TMZ-treated CTX-injured mice (CTX TMZ) 
5 days post-injury. At least six mice for each group were used. TMZ was administered 5mg/kg for 5 days by daily intraperitoneal (i.p.) 
injections from -1 to +4 days with respect to CTX muscle injury date T0. Data display the percentage of mRNAs relative to control, which 
was arbitrarily set as 100. Data shown are the mean ± s.e.m. from three experiments each performed in triplicate. *p ≤ 0.05 and **p ≤ 0.01 by 
two-tailed Student’s t-test. (B) To quantify regeneration due to CTX-induced injury, muscle sections of the injected muscles were analyzed 
5 days post-injury. Representative images only of the area with centronucleated myofibers of Laminin/DAPI stained cross-sections from 
at least three separate transverse planes of TA muscles damaged with CTX untreated (Ctrl) or treated (TMZ) with TMZ are shown. The 
percentage of centronucleated myofibers (Centr myofibers) on the whole section is indicated. Five untreated mice and and five TMZ-treated 
mice and at least 5000 myofibers from 5 untreated mice and at least 5000 myofibers from 5 TMZ-treated mice have been evaluated for 
the determination of cross-sectional area (CSA). Frequency histograms show the distribution of CSA measured only for centronucleated 
myofibers. Scale bar: 100 μm. (D) Same as (C) but at 15 days post-injury. The percentage of centronucleated myofibers (Centr myofibers) 
on the whole section is indicated (**p ≤ 0.01). (D) GSN extracts from untreated control mice (Ctrl), TMZ-treated control mice (TMZ), C26 
mice (C26) and TMZ-treated C26 mice (C26-TMZ) were assayed for Pax7, MyoD and Myogenin (Myog) protein levels. Protein levels 
of representative 3 out of 6 mice are shown. A lane between lane 6 and lane 7 was removed from the blot because of technical problems. 
ɑ-tubulin was used as loading control. Density of immunoreactive bands was calculated using the ImageQuant TL software from GE 
Healthcare Life normalized for α-tubulin. Each value indicates the mean± s.e.m. (reported as percentage of Ctrl) of the densitometric 
analysis on three independent immunoblots. **p ≤ 0.01 and ***p ≤ 0.001 by Student t-test.
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being SCs activated by exercise, our findings revealing 
a TMZ-induced enhancement of SC myogenic activity 
in vivo with production of new myofibers, further confirm 
the exercise-like effect of TMZ and thus its potential 
beneficial effects [59–62]. However, differently from 
our results, spontaneous physical activity in C26-bearing 
mice has recently been shown to reduce Pax7 expression, 
although no increased myogenesis (which is triggered by 
TMZ) was reported in this study [16]. In this context, it 
is relevant to underline that the effect of exercise might 
vary depending on its type and intensity. In fact, muscle 
micro-injuries that follow exercise induce a positive 
compensatory adaptation by an increase in SC activation 
[58, 63, 64]. However, if the intensity of exercise and 
damage is too strong, this might be deleterious for 
the muscle. Exercise mode and intensity need to be 
optimized in order to achieve the optimal modulation of 
SC activation, proliferation and differentiatiation [64]. 
Similarly, we also hypothesise that the concentration and 
timing of TMZ treatment must be moderate in order to be 
beneficial; in such a case, the activation of myogenesis 
by TMZ might contribute protecting skeletal muscle 
against the loss of mass in different pathologies, including 
cancer cachexia, and in ageing thanks to the formation 
of new myofibers. Moreover, in some conditions, a 
physiologically low response of muscle to exercise occurs, 
therefore, drugs mimicking some exercise-induced effects 
might potentially be more adequate in such cases.
Recent studies show that during myoblast 
differentiation the mitochondrial network gets remodeled 
by a first stage of mitochondrial fragmentation and 
clearance by autophagy followed by mitochondrial 
biogenesis mediated by PGC1ɑ [52]. Moreover, PGC1ɑ 
is normally up-regulated during myoblast differentiation 
and its overexpression is able to promote early muscle 
fiber formation in vitro [65]. The ability of TMZ to trigger 
PGC1ɑ would help sustain mitochondrial biogenesis 
necessary during differentiation which would enhance 
myofiber formation capacity.
Moreover, during differentiation of myoblasts into 
mature myotubes autophagy is robustly upregulated [52]. 
Our data show that the enhancement of autophagy is 
also induced by TMZ which is another process by which 
this metabolic modulator might contribute to accelerate 
myogenesis. Moreover, in some regeneration-impaired 
conditions, SC decline in number and functionality has been 
associated to alterations in autophagy [25, 26, 28]. Indeed, it 
has been found that promoting autophagy in geriatric mice 
reverses stem cell senescence and restores regeneration. 
Here we propose that the boosting effect on SC autophagy, 
PGC1ɑ expression and differentiative potential induced by 
TMZ might be potentially useful to improve the muscle 
myogenic capacity with production of new myofibers.
The enhancement of the myogenic potential and 
the reduction of the inflammatory citokine MCP1 during 
regeneration achieved by TMZ treatment, also make this 
drug an interesting candidate for enhancing the efficiency 
of skeletal muscle tissue engineering. Consistently, we 
have also found that exposure to TMZ affects myoblast 
orientation and promotes alignment [66]. Notably, tools 
able to control cell orientation are extremely relevant for 
correct artificial skeletal muscle engineering [67]. TMZ 
seems to enhance the recognition and adherence between 
myoblasts, which allows alignment. It has been found 
that myoblast recognition and fusion is associated with 
the up-regulation of specific membrane proteins and with 
a change in phospholipids and ganglioside composition 
of the external leaflet of plasma membranes [68]. We 
speculate that TMZ, by acting on lipid β-oxidation, might 
reorganize the phospholipid composition of sarcolemma, 
this enhancing alignment of myoblasts [69].
Taken together our data show that the metabolic 
modulator TMZ promotes new myofiber formation. 
Metabolism modulation is emerging as a major driver 
of the stem cell regenerative capacity and designing 
new strategies such as TMZ able to direct metabolism 
optimization in SCs might have a high impact on aging 
and regeneration-impaired disorders, including cachexia, 
as well as having implications in regenerative medicine 
approaches. Moreover, this effect on myogenesis might 
contribute to the modulation of protein synthesis and 
degradation mechanisms, previously detected for TMZ 
[47, 48]. This would enhance this drug’s potential 
repositioning and therapeutical use in fighting skeletal 
muscle wasting in chronic pathologies, e.g. as a 
rehabilitation tool when the conditions of the patient do 
not allow exercise or in association with other treatment 
to facilitate functional recovery.
MATERIALS AND METHODS
C2C12 cell culture and treatments
Murine C2C12 skeletal myoblasts (American Type 
Culture Collection; ATCC, Manassas, USA) tested for 
contamination were grown at 37°C in a 5% CO2 in an air 
humidified chamber in high glucose DMEM (Dulbecco’s 
Modified Eagle’s Medium, Thermofisher, Monza, Italy) 
with Glutamax, supplemented with 20% FBS and 1% 
penicillin/streptomycin (growth medium; GM). As the 
cells approached confluency, the GM was replaced with 
a differentiation medium (DM; DMEM supplemented 
with 2% horse serum). All reagents for media preparation 
were from Thermo Scientific. The medium was changed 
every second day. The DM incubation was performed 
with or without TMZ (Servier, Rome, Italy; Alfa Aesar 
Thermofisher, Monza, Italy). After ascertaining the 
instability of the TMZ powder, we always used fresh 
TMZ, not older than one month after the opening of the 
powder package.
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Satellite cell isolation, culture and treatments
Excised muscles were transferred into a plastic Petri 
dish with cold PBS and visible adipose and connective 
tissues were removed with a scalpel. Muscles were cut 
into small pieces using scissors and the shredded muscle 
pieces were treated using the Skeletal Muscle Dissociation 
Kit (Miltenyi Biotec, Calderara di Reno-Bologna, Italy) 
according to the manufacturer’s instructions in order 
to isolate satellite cells. Purity of the suspension was 
checked by flow cytometry by labeling cells with anti-
alfa7 integrin-PE conjugated antibody (Miltenyi Biotech) 
and ranged from 88% to 99% (Supplementary Figure 2). 
The purified cells were then centrifuged, resuspended in 
DMEM supplemented with 10% FBS, 20% HS and 3% 
CEE, and seeded in collagen precoated 35 mm dishes at 
37°C under 5% CO2. After two days, medium was changed 
and cells were treated or not with TMZ.
Fluorescence microscopy
Cells were treated as previously described [70] 
and stained with anti-MyHC 1:5 (MF20-Developmental 
Studies Hybridoma Bank at the University of Iowa), Myo 
D 1:100 (clone 5.8A, M3512, Dako, Agilent Technologies, 
Santa Clara, CA, USA) and Myogenin 1:100 (clone F5D, 
M3559, Dako) antibodies for 1 hour at RT. Cells were 
then washed in blocking buffer and incubated for 1 hour 
at 37°C with labeled anti-mouse 1:500 (Alexa Fluor 488; 
Molecular Probes, ThermoFisher) secondary antibody. 
Nuclei were stained with Hoechst 33342 (Sigma-Aldrich, 
Milan, Italy). The samples were mounted in FluoroMount 
mounting medium (Sigma-Aldrich). The images 
were acquired with an Olympus BX51/BX52 system 
microscope equipped with a Zeiss charge-coupled device 
(CCD) camera (Carl Zeiss, Milan, Italy).
Cell orientation measurement
Images of stained cells were used to study directional 
analysis of myocytes/myotubes. A segment crossing the 
longest part of each cell was added and used to analyze 
the distribution of cell direction by the OrientationJ 
(Distribution) plug-in of Image J. OrientationJ computes 
the local orientation and the local coherency (anisotropy 
factor) of an image. The coherency index r can range from 
0 (a perfect isotropy which is the existence of multiple cell 
directions) to 1 (in case of a perfect anisotropy which is 
the existence of a preferred-aligned-cell direction) [51].
Quantitative real-time PCR
C2C12 were lysed with RLT from RNeasy Mini Kit 
(Qiagen, Hilden, Germany) and RNA extracted following 
manufacturer’s instructions. For RT-PCR, cDNA was 
synthesized with oligo-dT by adding 1μg of RNA with 
GoScript Reverse Transcription System (Promega, 
Madison, Wisconsin, USA). Comparative real-time 
PCR was performed with the SYBR-green master mix 
(Promega) using the Stratagene MX3000 (Thermo Fisher 
Scientific). Data were normalized to 18S and a calibrator 
was used as internal control. Resulting data were analysed 
as indicate in by the MX3PRO software (v4.10) and fold-
change was determined by using the 2-ΔΔCT method as as 
previously described [71]. All reactions were performed in 
triplicate. The following primers were used:
18S Fw 5’-CCCTGCCCTTTGTACACACC-3’
Rv 5’-CGATCCGAGGGCCTCACTA-3’
MyoD Fw 5’-CCCCGGCGGCAGAATGGCTACG-3’
Rv 5’-GGTCTGGGTTCCCTGTTCTGTG-3’
Myogenin Fw 5’-GGGCCCCTGGAAGAAAAG-3’
Rv 5’-AGGAGGCGCTGTGGGAGT-3’
MyHC Fw 5′-CAAGTCATCGGTGTTTGTGG-3′
Rv 5′-TGTCGTACTTGGGAGGGTTC-3′
Desmin Fw 5’-GAGGTTGTCAGCGAGGCTAC-3’
Rv 5’-GAAAAGTGGCTGGGTGTGAT-3’
Pax7 Fw 5’-CAAGCCCTGAGTCTCCTCAC -3’
Rv 5’-CATGGGTAGATGGCACACTG-3’
MCP-1 Fw 5’-CTTCTGGGCCTGCTGTTCA-3’
Rv 5’-CCAGCCTACTCATTGGGATCA-3’
Atrogin-1 Fw 5′-ATGCACACTGGTGCAGAGAG-3′
Rv 5′-CCTAAGGTCCCAGACATCCA-3′
MuRF-1 Fw 5’-GACAGTCGCATTTCAAAGCA-3’
Rv 5’-AACGACCTCCAGACATGGAC-3’
Myostatin Fw 5’-CTGTAACCTTCCCAGGACCA-3’
Rv 5’-TCTTTTGGGTGCGATAATCC-3’
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Protein isolation and western blotting
Cells were washed twice in ice-cold PBS and 
lysed at 4°C in RIPA lysis buffer (50mM Tris/HCl, pH 
8, 150mM NaCl, 0.5% sodium-deoxycholate, 1mM 
EDTA, 0.1% NP40, 0.1% SDS) supplemented with 
Phosphatase Inhibitor Cocktail 2 and 3 (Sigma-Aldrich) 
and Complete Protease Inhibitor (Roche, Monza, Italy). A 
clear supernatant was obtained by centrifugation of lysates 
at 13,000 g for 20 min at 4°C. Protein concentration in 
the supernatant was determined by Bradford protein 
assay (Bio-Rad). Aliquots of total lysates were then 
separated by SDS-PAGE using Miniprotean precast gels 
(BioRad) and proteins were transferred to nitrocellulose 
membranes (BioRad) or to polyvinylidene difluoride 
(PVDF) membranes (BioRad). Membranes were blocked 
1h at RT with 5% non-fat milk in T-TBS (Tris-Buffered 
Saline with 0.05% Tween 20). Incubation with primary 
specific antibodies and horseradish peroxidase-conjugated 
secondary antibodies was performed in blocking solution 
for 1 hour at RT or over night at 4°C. We used antibodies 
against Laminin 1:1000 (L9393; Sigma-Aldrich), MyHC 
1:20 (MF20; Developmental Studies Hybridoma Bank 
at the University of Iowa), slow MyHC 1:1000 (M8421; 
Sigma-Aldrich), LC3 1:1000 (MBL–Medical & Biological 
Laboratories, Nagoya, Japan); PARP 1:1000 (9542; Cell 
Signalling, Danvers, MA, USA), Caspase 3 1:1000 (05-
654; Upstate Biotech, Lake Placid, NY, USA) [72], p62 
1:1000 (pm045; MBL), Myo D 1:1000 (clone 5.8A, 
Dako, M3512), Myogenin 1:1000 (clone F5D, Dako, 
M3559), Pax7 1:1 (DSHB), pAMPK 1:1000 (2535; Cell 
Signaling) [71] and PGC1ɑ 1:1000 (AB3242; Millipore). 
The appropriate secondary horseradish peroxidase-
conjugated antibodies from Jackson Immunoresearch 
were used in blocking solution (1:3000). Immunoreactive 
bands were visualised by SuperSignal West Pico 
Chemioluminescent substrate kit (Pierce). Equal loading 
of samples was confirmed by α-tubulin 1:1000 (T5168; 
Sigma-Aldrich) and bands quantified by densitometry 
using the ImageQuant TL software from GE Healthcare 
Life Sciences.
BrdU incorporation assay
5-bromo-2’-deoxyuridine (BrdU) incorporation assay 
was performed by using a commercial kit (Cell Proliferation 
kit, Ge Healthcare). Cells were seeded in P35 dishes (45 
103 cells) in GM. After 48 hours, cells were treated or not 
for 24 h with TMZ. Alternatively, cells were seeded in P35 
(90X103 cells) in GM. After 48 h, medium was replaced by 
differentiation medium DM and cells treated or not for 24 
hwith TMZ. During the last 4 h of treatments, BrdU labelling 
solution was added to cultures. After 30’ of fixation with 
fixative/denaturing solution (95% ethanol/0.1% acetic acid), 
cells were incubated with anti-BrdU monoclonal antibody for 
1 h at RT. Cells were then washed with PBS and incubated 
with a FITC-labeled secondary antibody (Molecular Probes, 
ThermoFisher) for 1 h at RT. After three final washes with 
PBS, cells were incubated with DAPI (Vector Laboratories, 
Peterborough, UK). Images were collected with a Nikon 
Eclipse TE 2000U fluorescence microscope and analyzed 
with ImageJ software.
Cell cycle analysis
Cell cycle was analyzed using propidium iodide 
(PI) (Sigma-Aldrich) staining. Briefly, after treatment 
with TMZ, cells were harvested using 0,05% Trypsin-
EDTA, washed two times in PBS and fixed with 70% 
cold ethanol. Cells were incubated 30 min at -20°C, then 
ethanol was removed and cells were resuspended in a 
PBS containing 50 μg/ml PI for 30 min at 4°C in the dark. 
Cells were then washed, resuspended in PBS, acquired 
and analyzed on a FACScalibur flow cytometer (Becton 
Dickinson) using CellQuest software.
Measurement of reactive oxygen species 
production
The reactive oxygen species (ROS)-sensitive probe 
DCF-DA (2’,7’-dichlorodihydrofluorescein-diacetate 
30 μM) was added to the culture medium for 1 h. Cells 
were harvested using 0,05% Trypsin-EDTA, then washed 
with PBS and analyzed immediately by flow cytometry 
using the FITC channel on a FACScalibur flow cytometer 
(Becton Dickinson, Milan, Italy).
Animals and experimental design
The animals were were obtained from Envigo S.R.L 
and housed on a 12-hour light/dark cycle with free access 
to a standard chow diet and water ad libitum during the 
whole experimental period, including the night before 
sacrifice. All procedures were approved by the ethics 
committee of Sapienza University of Rome-Unit of 
Histology and Medical Embryology and were performed 
in accordance with the current version of the Italian Law 
on the Protection of Animals. Experimental animals were 
cared for in compliance with the Italian Ministry of Health 
Guidelines (n° 86609 EEC, permit number 106/2007-B) 
and the Policy on Humane Care and Use of Laboratory 
Animals (NIH 1996).
C26 tumor-bearing mice
Balb-c male mice were randomized according to 
their body weight on the day before the treatments and 
divided into four groups, namely controls and tumor 
bearers, treated or not with the trimetazidine (TMZ). 
The number of the animals was chosen by a sample 
size simulation which allows a 85% power to detect the 
difference found in a previous study [14]. In more detail, 
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the first group (Ctrl; n=6) served as controls and included 
healthy mice inoculated with vehicle (saline); the second 
group (TMZ; n=6) included healthy mice receiving 
intraperitoneal (i.p.) injection of 5mg/kg TMZ once a 
day for 12 consecutive days; the third group (C26; n= 6) 
included tumor-bearing mice inoculated subcutaneously 
(s.c) dorsally with 5X105 C26 carcinoma cells; the fourth 
group (C26-TMZ; n= 6) was inoculated with C26 cells and 
the same day started receiving TMZ i.p. injection of 5mg/
kg TMZ once a day for 12 consecutive days. The day of 
sacrifice (12 days after tumor transplantation) the animals 
were anesthesized by isoflurane inhalation. Mice were 
then sacrificed by cervical dislocation and gastrocnemius 
(GSN) muscles were rapidly excised, weighed and frozen 
in liquid N2-cooled isopentane and finally stored at 
-80°C. GSN were homogenized by using a GentleMACS 
Dissociator (Miltenyi Biotec) and lysed in ice cold lysis 
buffer (10 mM Tris/HCl, pH 7.4, 5 mM EDTA, 5 mM 
EGTA, 1% Triton X-100, 130 mM NaCl, 0.1% SDS, 0.1% 
sodium deoxycholate).
Cardiotoxin-induced muscle regeneration
For the cardiotoxin muscle-crush injury/regeneration 
evaluation, 3 months old male C57BL/6 mice were 
used. Mice were anesthetized with an intraperitoneal 
injection of physiologic saline containing Avertin (250 
mg/Kg) and 10μM cardiotoxin (CTX) (Latoxan L81-
02-isolated from Naja pallida nigricollis snake venom) 
was then intramuscularly administered into the right 
TA in a volume of 60 μl with a 27-gauge needle. The 
contralateral untreated TA muscle served as control. For 
TMZ-treatment, animals were injected with 5mg/kg body 
weight/die TMZ in PBS or PBS alone (daily, from -1 to +4 
days with respect to muscle injury date T0). CTX-injured 
either PBS or TMZ-treated mice, were sacrificed at 5 
and 15 days after cardiotoxin injection and TA muscles 
were rapidly excised and frozen in liquid N2 and finally 
stored at -80°C. Dissociation of muscles was performed 
with Qiagen TissueRuptor and RNA isolation was 
performed using TRIreagent (Sigma-Aldrich) following 
manufacturer’s instructions.
Skeletal muscle immunofluorescence and 
morphometry
Serial muscle sections (9 μm) were obtained 
from the midbelly region of the TA muscles embedded 
in OCT (Bio-Optica, Milan, Italy) and snap frozen in 
liquid nitrogen-cooled isopentane (VWR International, 
Radnor, Pennsylvania, USA). A CM1900 cryostat 
(Leica, Wetzlar, Germany) at -20°C was used. 
Sections were fixed in 4% paraformaldehyde for 
10 min and washed 3 times with PBS for 2 min. After 
permeabilization with 0.2% Triton X-100 (Sigma-
Aldrich) and 1% BSA (Sigma-Aldrich) in PBS for 
30 min, the samples were blocked for 1h in 10% 
horse serum/ PBS at RT and then incubated for 1 h 
with anti-laminin (L9393 Sigma-Aldrich) antibody 
diluted in PBS (1:1000). The Alexa Fluor 488 anti 
rabbit IgG (A11008) from Thermo Fisher was used 
as secondary antibody. Nuclei were visualized with 
the DNA dye 40,6-diamidino-2-phenylindole (DAPI) 
(Thermo Fisher) and the samples were mounted in 
SlowFade Gold mounting media (Thermo Fisher). The 
images were acquired with a Leica TCS SP5 confocal 
microscope. In the stained muscle sections, automated 
CSA determination along the laminin-stained border 
of each fiber was evaluated by using Image J software 
(http://rsb.info.nih.gov/ij/) (NIH) [73]. To prevent 
errors in fiber border recognition (i.e. either the fibers 
might not be recognized or several fibers/non-fiber 
regions might be interpreted as a single fiber), a manual 
correction of myofiber border misinterpretation was 
performed.
Statistics
All experiments were performed at least four times, 
unless otherwise indicated. Data are presented as mean ± 
standard error of the mean (s.e.m.). Statistical differences 
between groups were verified by Student’s t-test (2-tailed). 
*P < 0.05 was considered significant.
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